NasdaqGM:ZLAB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune, and infectious diseases in China. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Zai Lab's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ZLAB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ZLAB's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

22.1%

ZLAB

4.5%

US Biotechs

0.3%

US Market


1 Year Return

254.2%

ZLAB

40.6%

US Biotechs

21.1%

US Market

Return vs Industry: ZLAB exceeded the US Biotechs industry which returned 36.8% over the past year.

Return vs Market: ZLAB exceeded the US Market which returned 19.5% over the past year.


Shareholder returns

ZLABIndustryMarket
7 Day22.1%4.5%0.3%
30 Day47.5%6.8%3.3%
90 Day117.1%27.2%14.2%
1 Year254.2%254.2%42.9%40.6%23.8%21.1%
3 Year679.9%679.9%28.8%22.1%45.0%35.4%
5 Yearn/a51.3%39.6%127.7%102.3%

Long-Term Price Volatility Vs. Market

How volatile is Zai Lab's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Zai Lab undervalued compared to its fair value and its price relative to the market?

29.71x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: ZLAB ($184.69) is trading above our estimate of fair value ($110.36)

Significantly Below Fair Value: ZLAB is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ZLAB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ZLAB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ZLAB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ZLAB is overvalued based on its PB Ratio (29.7x) compared to the US Biotechs industry average (4.2x).


Next Steps

Future Growth

How is Zai Lab forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

55.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZLAB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZLAB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZLAB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ZLAB's revenue (50.5% per year) is forecast to grow faster than the US market (10.3% per year).

High Growth Revenue: ZLAB's revenue (50.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ZLAB is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Zai Lab performed over the past 5 years?

-49.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ZLAB is currently unprofitable.

Growing Profit Margin: ZLAB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ZLAB is unprofitable, and losses have increased over the past 5 years at a rate of 49.9% per year.

Accelerating Growth: Unable to compare ZLAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZLAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: ZLAB has a negative Return on Equity (-51.65%), as it is currently unprofitable.


Next Steps

Financial Health

How is Zai Lab's financial position?


Financial Position Analysis

Short Term Liabilities: ZLAB's short term assets ($484.9M) exceed its short term liabilities ($56.6M).

Long Term Liabilities: ZLAB's short term assets ($484.9M) exceed its long term liabilities ($26.2M).


Debt to Equity History and Analysis

Debt Level: ZLAB's debt to equity ratio (0.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if ZLAB's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ZLAB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ZLAB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Zai Lab current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ZLAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ZLAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ZLAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZLAB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ZLAB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Samantha Du (54 yo)

7yrs

Tenure

Dr. Ying Du, also known as Samantha, Ph.D., serves as Founding Managing Director at Quan Capital. She serves as Venture Partner at Sequoia Capital China. Dr. Du serves as an adjunct professor at Fudan Univ...


Leadership Team

NamePositionTenureCompensationOwnership
Ying Du
Founder7yrsno data1.21%
$ 196.0m
Tao Fu
President4yrsno data0.33%
$ 54.4m
Ki Chul Cho
Chief Financial Officer2.83yrsno data0.068%
$ 11.1m
Harald Reinhart
Chief Medical Officer of Autoimmune & Infectious Diseases4yrsno data0%
$ 0
Yi Liang
Chief Commercial Officer & President of Greater China2.58yrsno data0.12%
$ 19.2m
Frazor Edmondson
Chief Legal Officer0.42yrno data0.028%
$ 4.5m
Ning Xu
Executive VP & Head of Clinical Operations7yrsno datano data
Jonathan J. Wang
Senior VP & Head of Business Development7yrsno datano data
James Yan
Chief Operating Officer of R&D6yrsno datano data
Yunpeng Su
VP & Head of Biologics Discovery - China2.42yrsno datano data
Alan Sandler
President and Head of Global Development & Oncology0.083yrno data0.034%
$ 5.5m
Lei Shi
Executive Director of Antibodyno datano datano data

2.8yrs

Average Tenure

49yo

Average Age

Experienced Management: ZLAB's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ying Du
Founder7yrsno data1.21%
$ 196.0m
Tao Fu
President4yrsno data0.33%
$ 54.4m
Peter Wirth
Director & Senior Advisor4yrsno data0.38%
$ 61.9m
John Diekman
Independent Director4yrsno data0.068%
$ 11.1m
Wing Yu Leung
Director7yrsno datano data
Neal Rosen
Member of Scientific Advisory Board5yrsno datano data
Richard Flavell
Member of Scientific Advisory Board4yrsno datano data
William Lis
Independent Director2.25yrsno data0.028%
$ 4.5m
Alex Adjei
Member of Scientific Advisory Boardno datano datano data
Lieping Chen
Member of Scientific Advisory Board1.92yrsno datano data
Kai-Xian Chen
Independent Director2.42yrsno data0.029%
$ 4.6m
Timothy A. Yap
Member of Scientific Advisory Board1.08yrsno datano data

4.0yrs

Average Tenure

63.5yo

Average Age

Experienced Board: ZLAB's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33%.


Top Shareholders

Company Information

Zai Lab Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zai Lab Limited
  • Ticker: ZLAB
  • Exchange: NasdaqGM
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$16.257b
  • Shares outstanding: 88.02m
  • Website: https://www.zailaboratory.com

Number of Employees


Location

  • Zai Lab Limited
  • Building 1, Jinchuang Plaza
  • 4th Floor
  • Shanghai
  • 201210
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZLABNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDSep 2017
1ZLDB (Deutsche Boerse AG)YesOrdinary SharesDEEURSep 2017
ZLAB NBMV (Bolsa Mexicana de Valores)YesOrdinary SharesMXMXNSep 2017
9688SEHK (The Stock Exchange of Hong Kong Ltd.)Ordinary SharesHKHKDSep 2020

Biography

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune,...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/20 00:27
End of Day Share Price2021/01/19 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.